Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

89%

8 trials in Phase 3/4

Results Transparency

89%

8 of 9 completed trials have results

Key Signals

8 with results

Enrollment Performance

Analytics

Phase 4

8(88.9%)

Phase 2

1(11.1%)

9Total

Phase 4(8)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT06104423Phase 4Completed

Open-label inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients

Role: lead

NCT05513937Phase 4Completed

Effectiveness and Safety of Combination of Nebivolol and Amlodipine in Hypertensive Patients Versus Each Monotherapy

Role: lead

NCT05170841Phase 4Completed

Study Evaluating Dexketoprofen Trometamol/Tramadol Hydrochloride Analgesic Efficacy in Acute Low Back Pain

Role: lead

NCT05279807Phase 4Completed

Effectiveness and Safety of Combination of Amlodipine and Zofenopril in Hypertensive Patients Versus Each Monotherapy

Role: lead

NCT05257148Phase 4Completed

Effectiveness and Safety of Combination of Nebivolol and Zofenopril in Hypertensive patIents Versus Each Monotherapy

Role: lead

NCT03953989Phase 2Completed

Effects of Ranolazine on Coronary Microvascular Dysfunction in Patients With Hypertrophic Cardiomyopathy

Role: collaborator

NCT02761252Phase 4Completed

Efficacy of Co-administration of Bilastine and Montelukast in Patients With SARC and Asthma

Role: lead

NCT02500641Phase 4Completed

Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout

Role: lead

NCT02576041Phase 4Completed

Effects of Bilastine on F1 Simulator Driving Performance in Patients Affected by Allergic Rhinitis and/or Urticaria

Role: lead

All 9 trials loaded